التفاصيل البيبلوغرافية
| العنوان: |
Dual orexin receptor antagonists for insomnia in youth with neurodevelopmental disorders: a case series and review |
| المؤلفون: |
Besterman, Aaron D, Jeste, Shafali S |
| المصدر: |
European Child & Adolescent Psychiatry, vol 32, iss 3 |
| بيانات النشر: |
eScholarship, University of California |
| سنة النشر: |
2023 |
| المجموعة: |
University of California: eScholarship |
| مصطلحات موضوعية: |
Biomedical and Clinical Sciences, Clinical Sciences, Psychology, Clinical Trials and Supportive Activities, Pediatric, Brain Disorders, Neurosciences, Intellectual and Developmental Disabilities (IDD), Mental Health, Behavioral and Social Science, Sleep Research, Clinical Research, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, 5.1 Pharmaceuticals, Development of treatments and therapeutic interventions, Child, Humans, Adolescent, Sleep Initiation and Maintenance Disorders, Orexin Receptor Antagonists, Sleep, Neurodevelopmental Disorders, Research, Insomnia, Dual orexin receptor antagonists, Sleep disorders, Developmental & Child Psychology, Applied and developmental psychology, Clinical and health psychology |
| جغرافية الموضوع: |
527 - 531 |
| الوصف: |
Insomnia is a common, impairing, and difficult-to-treat comorbidity in children with neurodevelopmental disorders (NDDs). Behavioral interventions can be challenging because of developmental and behavioral features that interfere with treatment. Medication management also can be difficult due to a high burden of side effects, a high rate of paradoxical responses, and frequent treatment resistance. Therefore, new treatment options for insomnia in children with NDDs are needed. Dual orexin receptor antagonists (DORAs) are a relatively new class of pharmacotherapeutics that induce sleep by inhibiting the orexin signaling pathway. To date, there is little safety or efficacy data on the use of DORAs in children with NDDs. We present four patients with NDDs and insomnia that we treated with the DORA, suvorexant. We found that patients had a wide range of responses, with one patient displaying a robust improvement in sleep onset and maintenance, while another had significant improvement in insomnia symptoms on combination therapy with trazodone. Our final two patients had mild or no benefit from suvorexant therapy. Further research is necessary to establish the safety and efficacy of DORAs in this population and to identify predictive factors, such as specific neurogenetic diagnoses or clinical features, of a positive treatment response. |
| نوع الوثيقة: |
article in journal/newspaper |
| وصف الملف: |
application/pdf |
| اللغة: |
unknown |
| العلاقة: |
qt8769g7sf; https://escholarship.org/uc/item/8769g7sfTest |
| الإتاحة: |
https://escholarship.org/uc/item/8769g7sfTest |
| حقوق: |
public |
| رقم الانضمام: |
edsbas.401E5947 |
| قاعدة البيانات: |
BASE |
